2026-02-11, 6:49:35 a.m.
LAS VEGAS, Nevada — February 11, 2026 — Leads & Copy — Avaí Bio, Inc. (OTCQB:AVAI), formerly Avant Technologies, Inc., has completed its corporate name change, effective today. The company’s common stock will continue trading under the ticker symbol AVAI on OTC Markets, with no change to the CUSIP number.
The rebranding reflects the company’s sharpened focus on advancing treatments for type 1 and insulin-dependent type 2 diabetes, age-related diseases, and healthy longevity through genetically modified cellular platforms and protective encapsulation technologies. Shareholders, partners, and investors can access the updated corporate identity and pipeline details at the new website: https://www.avaibio.com.
According to Chris Winter, CEO, the name change marks a defining moment in the company’s evolution from a technology-focused entity to a biotechnology innovator in cellular medicine. Winter said Avaí Bio better captures the mission to deliver life-changing therapies that address unmet needs in diabetes management, age-related diseases, and anti-aging.
The company aims to leverage genetically engineered cell lines, state-of-the-art encapsulation to shield cells from immune rejection, and strategic joint ventures to accelerate progress toward functional cures and extended healthy lifespans.
Key elements of Avaí Bio’s pipeline include:
Diabetes Development Program: This program involves genetically modified cell lines engineered to produce, store, and secrete insulin, combined with proprietary encapsulation for immune protection. The aim is to provide a sustainable, immunosuppression-free solution for type 1 and insulin-dependent type 2 diabetes.
α-Klotho Development Program: This program focuses on the advancement of a “longevity protein” overexpression cell line to combat age-related decline, targeting broader anti-aging and chronic disease applications.
Strategic collaborations, including the formation of Insulinova (diabetes program) and Klothonova (α-Klotho program) will drive clinical translation through joint research, licensing, and encapsulation expertise.
By rebranding to Avaí Bio, the Company aligns its corporate identity with its core operations in sourcing, developing, and protecting advanced cellular therapies–positioning it to attract top-tier partnerships, accelerate R&D, and bring groundbreaking treatments closer to patients.
Avaí Bio, Inc. is focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
More information about Avaí Bio can be found at https://www.avaibio.com
Source: Avaí Bio, Inc.
